Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation

Dana G. Wolf, Avichai Shimoni, Igor B. Resnick, Thomas Stamminger, Avidan U. Neumann, Sunwen Chou, Thomas Efferth, Orit Caplan, Jessica Rose, Arnon Nagler, Manfred Marschall

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

The anti-malaria drug artesunate has been shown to be an effective inhibitor of cytomegalovirus (CMV) in vitro, in an experimental animal model, and in a recent single-case clinical use. In this first case-series of 6 stem cell transplant recipients who received preemptive artesunate treatment for CMV infection, we have examined the viral kinetics following institution of artesunate, and employed first-phase viral kinetics studies to calculate its antiviral effectiveness. Two patients demonstrated a rapid 0.8-2.1 log viral load decline by 7. days, with a viral decay half-live of 0.9-1.9. days. Four patients demonstrated a continued yet stalled viral growth slope during treatment. No adverse events were noted in treatment courses of up to 28. days. Overall, a divergent antiviral efficacy was revealed, ranging from 43% to 90%, which appeared to be primarily dependent on the virus baseline growth dynamics. Further dose escalation studies are needed to examine the role of artesunate in the treatment of CMV infection in the transplantation setting.

Original languageEnglish (US)
Pages (from-to)183-186
Number of pages4
JournalAntiviral Research
Volume90
Issue number3
DOIs
StatePublished - Jun 2011

Fingerprint

Hematopoietic Stem Cell Transplantation
Cytomegalovirus
Cytomegalovirus Infections
Antiviral Agents
Therapeutics
Growth
Viral Load
Malaria
Stem Cells
Animal Models
Transplantation
Viruses
Transplants
artesunate
Pharmaceutical Preparations

Keywords

  • Antiviral drugs
  • Artesunate
  • Cytomegalovirus
  • Viral kinetics

ASJC Scopus subject areas

  • Virology
  • Pharmacology

Cite this

Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation. / Wolf, Dana G.; Shimoni, Avichai; Resnick, Igor B.; Stamminger, Thomas; Neumann, Avidan U.; Chou, Sunwen; Efferth, Thomas; Caplan, Orit; Rose, Jessica; Nagler, Arnon; Marschall, Manfred.

In: Antiviral Research, Vol. 90, No. 3, 06.2011, p. 183-186.

Research output: Contribution to journalArticle

Wolf, DG, Shimoni, A, Resnick, IB, Stamminger, T, Neumann, AU, Chou, S, Efferth, T, Caplan, O, Rose, J, Nagler, A & Marschall, M 2011, 'Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation', Antiviral Research, vol. 90, no. 3, pp. 183-186. https://doi.org/10.1016/j.antiviral.2011.03.184
Wolf, Dana G. ; Shimoni, Avichai ; Resnick, Igor B. ; Stamminger, Thomas ; Neumann, Avidan U. ; Chou, Sunwen ; Efferth, Thomas ; Caplan, Orit ; Rose, Jessica ; Nagler, Arnon ; Marschall, Manfred. / Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation. In: Antiviral Research. 2011 ; Vol. 90, No. 3. pp. 183-186.
@article{b425c0afe02e487394c824713f38ac9b,
title = "Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation",
abstract = "The anti-malaria drug artesunate has been shown to be an effective inhibitor of cytomegalovirus (CMV) in vitro, in an experimental animal model, and in a recent single-case clinical use. In this first case-series of 6 stem cell transplant recipients who received preemptive artesunate treatment for CMV infection, we have examined the viral kinetics following institution of artesunate, and employed first-phase viral kinetics studies to calculate its antiviral effectiveness. Two patients demonstrated a rapid 0.8-2.1 log viral load decline by 7. days, with a viral decay half-live of 0.9-1.9. days. Four patients demonstrated a continued yet stalled viral growth slope during treatment. No adverse events were noted in treatment courses of up to 28. days. Overall, a divergent antiviral efficacy was revealed, ranging from 43{\%} to 90{\%}, which appeared to be primarily dependent on the virus baseline growth dynamics. Further dose escalation studies are needed to examine the role of artesunate in the treatment of CMV infection in the transplantation setting.",
keywords = "Antiviral drugs, Artesunate, Cytomegalovirus, Viral kinetics",
author = "Wolf, {Dana G.} and Avichai Shimoni and Resnick, {Igor B.} and Thomas Stamminger and Neumann, {Avidan U.} and Sunwen Chou and Thomas Efferth and Orit Caplan and Jessica Rose and Arnon Nagler and Manfred Marschall",
year = "2011",
month = "6",
doi = "10.1016/j.antiviral.2011.03.184",
language = "English (US)",
volume = "90",
pages = "183--186",
journal = "Antiviral Research",
issn = "0166-3542",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation

AU - Wolf, Dana G.

AU - Shimoni, Avichai

AU - Resnick, Igor B.

AU - Stamminger, Thomas

AU - Neumann, Avidan U.

AU - Chou, Sunwen

AU - Efferth, Thomas

AU - Caplan, Orit

AU - Rose, Jessica

AU - Nagler, Arnon

AU - Marschall, Manfred

PY - 2011/6

Y1 - 2011/6

N2 - The anti-malaria drug artesunate has been shown to be an effective inhibitor of cytomegalovirus (CMV) in vitro, in an experimental animal model, and in a recent single-case clinical use. In this first case-series of 6 stem cell transplant recipients who received preemptive artesunate treatment for CMV infection, we have examined the viral kinetics following institution of artesunate, and employed first-phase viral kinetics studies to calculate its antiviral effectiveness. Two patients demonstrated a rapid 0.8-2.1 log viral load decline by 7. days, with a viral decay half-live of 0.9-1.9. days. Four patients demonstrated a continued yet stalled viral growth slope during treatment. No adverse events were noted in treatment courses of up to 28. days. Overall, a divergent antiviral efficacy was revealed, ranging from 43% to 90%, which appeared to be primarily dependent on the virus baseline growth dynamics. Further dose escalation studies are needed to examine the role of artesunate in the treatment of CMV infection in the transplantation setting.

AB - The anti-malaria drug artesunate has been shown to be an effective inhibitor of cytomegalovirus (CMV) in vitro, in an experimental animal model, and in a recent single-case clinical use. In this first case-series of 6 stem cell transplant recipients who received preemptive artesunate treatment for CMV infection, we have examined the viral kinetics following institution of artesunate, and employed first-phase viral kinetics studies to calculate its antiviral effectiveness. Two patients demonstrated a rapid 0.8-2.1 log viral load decline by 7. days, with a viral decay half-live of 0.9-1.9. days. Four patients demonstrated a continued yet stalled viral growth slope during treatment. No adverse events were noted in treatment courses of up to 28. days. Overall, a divergent antiviral efficacy was revealed, ranging from 43% to 90%, which appeared to be primarily dependent on the virus baseline growth dynamics. Further dose escalation studies are needed to examine the role of artesunate in the treatment of CMV infection in the transplantation setting.

KW - Antiviral drugs

KW - Artesunate

KW - Cytomegalovirus

KW - Viral kinetics

UR - http://www.scopus.com/inward/record.url?scp=79955086441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955086441&partnerID=8YFLogxK

U2 - 10.1016/j.antiviral.2011.03.184

DO - 10.1016/j.antiviral.2011.03.184

M3 - Article

C2 - 21443904

AN - SCOPUS:79955086441

VL - 90

SP - 183

EP - 186

JO - Antiviral Research

JF - Antiviral Research

SN - 0166-3542

IS - 3

ER -